Core Viewpoint - WuXi AppTec (02268) saw its stock price rise over 7%, reaching a new high of HKD 75.8, following the announcement of a subscription agreement with WuXi Biologics [1] Group 1: Stock Performance - The stock price increased by 4.97% to HKD 73.9, with a trading volume of HKD 201 million [1] Group 2: Subscription Agreement - WuXi AppTec announced a subscription agreement signed with WuXi Biologics on September 3, involving the issuance of 24.13 million new shares, representing approximately 1.96% of the company's issued share capital as of the last practicable date [1] - Following the completion of the subscription, WuXi Biologics' ownership will increase from 48.81% to 50.74%, while the public shareholders' stake will decrease from 28.76% to 28.21% [1] Group 3: Use of Proceeds - The net proceeds from the subscription are approximately HKD 1.414 billion, with about 90% allocated for expanding the production capacity of bioconjugates and related products, and around 10% for general operational funding needs [1]
药明合联涨超7%再创新高 公司敲定认购协议事项 药明生物持股比例将超50%